Solly Chedid, MD
Hematology & Oncology · Pascagoula, MSNPI 1972586188
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,209,266 of the $1,717,785 with a category attached, or 70.4%. 60 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 25.4% of the total. Among hematology & oncology clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,159 payments — averaging $795.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$436K
- Merck$186K
- E.r. Squibb & Sons, L.L.C.$184K
- Ipsen Biopharmaceuticals, Inc$135K
- Daiichi Sankyo Inc.$130K
- Bristol Myers Squibb$104K
- plus $543K from 54 others
What the payments were for
- Consulting fees$288,49917%
- Speaking & faculty fees$1,209,26670%
- Travel & lodging$180,86511%
- Food & beverage$38,6162%
- Education$5390%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,717,785 in reported general payments places this provider in the 95th percentile of 57 hematology & oncology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CalquenceAcalabrutinib Maleate | 47 | $655,609 |
| BesremiRopeginterferon Alfa-2b-Njft | 25 | $346,718 |
| PomalystPomalidomide | 12 | $269,760 |
| ErivedgeVismodegib | 11 | $138,167 |
| Abiraterone Acetate | 11 | $36,699 |
| EliquisApixaban | 37 | $27,938 |
| XareltoRivaroxaban | 16 | $16,385 |
| Morphine Sulfate ErMorphine Sulfate | 73 | $2,280 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 84 | $2,001 |
| Ondansetron Hcl | 126 | $1,461 |
| Dexamethasone | 77 | $1,313 |
| Oxycodone Hcl | 54 | $1,159 |
| ValacyclovirValacyclovir Hcl | 23 | $1,111 |
| Naloxone Hcl | 16 | $1,097 |
| Olanzapine | 91 | $1,082 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence | $52,286 | $655,60947 claims |
| Pharmaessentia USA CorporationBesremi | $29,161 | $346,71825 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $183,989 | $269,76012 claims |
| Genentech USA, Inc.Erivedge | $5,315 | $138,16711 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $3,611 | $36,69911 claims |
| PfizerEliquis | $51,232 | $27,93837 claims |
| Johnson & JohnsonXarelto | $16,877 | $16,38516 claims |
| Lilly USA, LLCOlanzapine | $251 | $1,08291 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $50 | $28549 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 57 hematology & oncology providers in Mississippi.
Other hematology & oncology in Pascagoula
- Daniel PattersonPascagoula$36K
- Cory CarterPascagoula$3K
- Carter MilnerJackson$248K
- Guangzhi QuJackson$59K
- Jennifer EubanksMeridian$44K
- John HeneganJackson$35K
- Pamela TuliGulfport$27K
- Sonia BennSouthaven$26K
- Ronald DelrieMcComb$24K
- Matthew CassellMeridian$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.